A Must See Satellite Symposium
Don’t miss this engaging presentation featuring a rapid-fire series of
moderate to severe atopic dermatitis (AD) patient cases.

Register Now

Monday, January 16, 2017

12:55 PM – 1:00 PM
CME Symposium / Q&A Session
1:00 PM – 1:45 PM

The Fairmont Orchid
Promenade Ballroom 2 and 3
1 North Kaniku Drive
Kohala Coast, HI 96743

Register Now

This event is being held in conjunction with the
2017 Winter Clinical Dermatology Conference – Hawaii®

This program is independent and is not part of the official conference agenda as planned by the Program Committee of the 2017 Winter Clinical Dermatology Conference – Hawaii®

12:55 PM – 1:00 PM Registration
1:00 PM – 1:05 PM Welcome and Introductions
  Jonathan I. Silverberg, MD, PhD, MPH
1:05 PM – 1:25 PM A Precision Medicine Approach to Managing Moderate to Severe AD
  Jonathan I. Silverberg, MD, PhD, MPH
1:25 PM – 1:35 PM Working Collaboratively with the Patient and Caregiver in AD
  Jonathan I. Silverberg, MD, PhD, MPH
1:35 PM – 1:45 PM Q&A and Discussion
  Jonathan I. Silverberg, MD, PhD, MPH


Jonathan I. Silverberg, MD, PhD, MPH
Assistant Professor, Departments of Dermatology,
  Preventive Medicine and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary
  Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, Illinois

This activity has been designed to meet the educational needs of dermatology clinicians who manage patients with moderate to severe atopic dermatitis (AD).

Many physicians who treat patients with AD are not aware of recent changes in the understanding of AD pathogenesis and the emergence of treatment strategies to more successfully target the cause of the disease. Furthermore, the guidelines for AD treatment differ between allergists and dermatologists, leading to wide divergences in how individual patients may be cared for by each specialty. Lack of appropriate treatment strategies in AD may fail to prevent the “atopic march” as dermatitis progresses to allergic rhinitis, and then asthma. Finally, one of the greatest barriers to the treatment of AD is the lack of adherence to prescribed treatment regimens, which is rooted in the inability of physicians to adequately include patients in their decision- making process and address patients’ concerns about their disease, their impaired quality of life, and their desires with regard to treatment.

After completing this activity, the participant should be better able to:

  • Describe the pathogenesis of AD and discuss how the underlying pathology of the disease can be used to direct therapy
  • Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate to severe AD
  • Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD
  • Engage the patient as a partner in their care plan to ensure best treatment adherence and outcomes


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

There is no fee for this educational activity.

Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact RMEI Medical Education, LLC prior to the live event at (866) 770-RMEI.

Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent medical educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.

Register Now



Facebook Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found at www.RMEI.com or by calling toll-free (866) 770-RMEI.